Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jiangsu Hengrui Medicine Co., Ltd.

https://www.hrs.com.cn/index.html

Latest From Jiangsu Hengrui Medicine Co., Ltd.

Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants

With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.

China Financing

CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global

While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.

Research & Development China

Shanghai Pharma Manufacturing Halves In April

China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.

China Coronavirus COVID-19

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.

Commercial Executive Changes
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register